In patients with MDS-f, survival differences were also noted among those with MDS with EB (n = 13, LFS 21.9 months, OS 22.2 months), MDS with mutated TP53 (n = 4, LFS 5.2 months, OS 5.9 months), and MDS/AML with MDS-related gene mutations (n = 6, LFS 12.7 months, OS 13.9 months) when classified by the ICC (pairwise comparison P value all <0.05 for OS, Supplementary Fig. 13). This evidence concerns the gene TP53 and acute myeloid leukemia.